Lunit vs MedGenome

Lunit has a disclosed valuation of $829M, while MedGenome's valuation is not publicly available, making a direct size comparison difficult. Lunit employs 300 people.

Lunit has raised more in total funding at $150M, compared to MedGenome's $50M — a gap of $100M. Combined, the two companies have completed 4 known funding rounds.

Both Lunit and MedGenome share the same Awaira Score of 63/100. The Awaira Score is a composite metric that factors in valuation, total funding raised, company stage, employee count, and market category.

Lunit was founded by Brandon Suh in 2013. MedGenome was founded by Sam Santhosh in 2013. Visit each company's profile on Awaira for a full founder biography.

Lunit: Lunit is a South Korean AI healthcare company founded in 2013 that specializes in diagnostic imaging analysis using artificial intelligence. The company develops machine learning algorithms designed to assist radiologists in detecting abnormalities across medical imaging modalities, particularly in chest radiography, breast cancer screening, and CT scans. Lunit's core platform uses deep learning to analyze medical images and provide clinical decision support, aiming to improve diagnostic accuracy and efficiency in healthcare settings. The company's primary products include Lunit INSIGHT, a software solution that integrates with existing hospital infrastructure and picture archiving systems. Lunit has established a presence across Asia, Europe, and other regions, with its technology deployed in hospitals and diagnostic centers. The company went public on the Korean stock exchange, achieving a valuation of $0.8 billion. With $150 million in total funding raised through various rounds before its public listing, Lunit operates in a competitive segment alongside companies like Zebra Medical Vision, Arterys, and various regional competitors. The company faces competition from both specialized AI diagnostic firms and larger healthcare technology providers developing similar capabilities. Lunit's growth trajectory reflects increasing adoption of AI in medical imaging across Asia-Pacific markets, where regulatory pathways and healthcare infrastructure continue to evolve to accommodate such technologies. Lunit is among the few AI medical imaging companies to achieve public market status, particularly from South Korea, reflecting regional strength in healthcare technology innovation. MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system.

Both Lunit and MedGenome were founded in the same year — 2013. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Lunit has approximately 300 employees, while MedGenome has approximately 200-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Lunit and MedGenome are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.